Sarepta Therapeutics Inc (SRPT)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Gross profit (ttm)	US$ in thousands	1,574,161	1,400,658	1,319,968	1,237,415	1,092,993	968,016	863,542	832,120	793,024	735,113	710,758	659,640	604,838	557,855	520,802	500,250	476,717	438,529	395,624	350,351
Revenue (ttm)	US$ in thousands	1,901,979	1,640,348	1,504,993	1,403,300	1,243,336	1,104,982	1,003,434	975,683	933,013	876,047	835,184	765,786	701,887	645,564	600,082	573,356	540,099	495,074	450,191	407,496
Gross profit margin		82.76%	85.39%	87.71%	88.18%	87.91%	87.60%	86.06%	85.29%	85.00%	83.91%	85.10%	86.14%	86.17%	86.41%	86.79%	87.25%	88.26%	88.58%	87.88%	85.98%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $1,574,161K ÷ $1,901,979K
= 82.76%

Sarepta Therapeutics Inc has shown a relatively stable gross profit margin over the past few years, with fluctuations within a certain range. The gross profit margin started around 85-89% in early 2020 and gradually decreased to around 83-86% by the end of 2022. However, there was a slight increase to 87.91% by the end of December 2023, followed by a subsequent decrease to 82.76% by the end of December 2024.

Overall, Sarepta Therapeutics Inc maintained a strong gross profit margin throughout the period under review, indicating an efficient cost structure and effective pricing strategies. It is important for the company to monitor and manage its cost of goods sold to sustain a healthy gross profit margin and ensure profitability in the long run.